Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Rhea-AI Summary

Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its participation in the upcoming H.C. Wainwright "HCW@Home" Series. The company will engage in a fireside chat on July 30, 2025, at 11:00 a.m. ET.

Investors can access the webcast through registration or via the Investors section of Nkarta's website. A replay will be available on www.nkartatx.com for approximately 90 days following the event.

News Market Reaction – NKTX

+7.21%

1 alert

+7.21% Session move

$147.59M Market Cap

1.15K Volume

In the trading session that priced this news, NKTX gained 7.21%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series.

H.C Wainwright “HCW@Home with Nkarta, Inc.”
July 30, 2025
11:00 a.m. ET – fireside chat

Register for the webcast here. A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com

FAQ

When is Nkarta (NKTX) presenting at the H.C. Wainwright conference?

Nkarta will participate in a fireside chat on July 30, 2025, at 11:00 a.m. ET as part of the H.C. Wainwright 'HCW@Home' Series.

How can investors access Nkarta's (NKTX) H.C. Wainwright presentation?

Investors can access the presentation through registration for the webcast or via the Investors section of Nkarta's website at www.nkartatx.com.

How long will the replay of Nkarta's (NKTX) presentation be available?

A replay of the presentation will be archived on Nkarta's website for approximately 90 days following the event.

What type of therapies is Nkarta (NKTX) developing?

Nkarta is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies.